Press Releases April 29, 2026 04:45 PM

Unitil Shareholders Elect Directors at Annual Meeting

Unitil Elects Board Directors and Secures Strong Shareholder Support for Executive Compensation at 2026 Annual Meeting

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
UTL

Unitil Corporation held its 2026 Annual Meeting where shareholders elected three directors to the Board for three-year terms, ratified Deloitte & Touche as auditors, and approved the executive compensation plan with 96% support. CEO Thomas P. Meissner Jr. reviewed 2025 highlights including acquisitions and future strategies for sustainable growth.

Unitil Shareholders Elect Directors at Annual Meeting
UTL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Three directors elected to the Board for three-year terms, ensuring leadership continuity.
  • Shareholders approved the advisory 'say on pay' executive compensation plan with a high 96% majority.
  • CEO highlighted 2025 operational achievements and future strategies aimed at long-term sustainable value creation.
  • Sectors impacted include utilities, energy delivery, and regional infrastructure in New England.

HAMPTON, N.H., April 29, 2026 (GLOBE NEWSWIRE) -- Unitil Corporation (NYSE:UTL) (unitil.com) held its Annual Meeting of Shareholders today at the corporate office in Hampton, New Hampshire. Shareholders elected Neveen F. Awad, Winfield S. Brown and Mark H. Collin to the Board of Directors, each for a term of three years. Shareholders also ratified the selection of Deloitte & Touche, LLP as independent registered public accountants for 2026.  

Additionally, the required shareholder advisory vote concerning executive compensation, also known as “say on pay,” was approved by 96% of shareholders.

Following the business of the formal meeting, Thomas P. Meissner, Jr., Unitil's Chairman and Chief Executive Officer, presented highlights from 2025 including recent acquisitions, and the Company’s strategies for creating long-term sustainable value. Mr. Meissner's presentation is available in the Investor Relations section of the Company’s website at investors.unitil.com.

About Unitil Corporation

Unitil Corporation provides energy for life by safely and reliably delivering electricity and natural gas in New England. We are committed to the communities we serve and to developing people, business practices, and technologies that lead to the delivery of dependable, more efficient energy. Unitil Corporation is a public utility holding company with operations in Maine, New Hampshire and Massachusetts. Together, Unitil’s operating utilities serve approximately 110,100 electric customers and 105,000 natural gas customers. For more information about our people, technologies, and community involvement please visit unitil.com.

This press release contains forward-looking statements, which are subject to the inherent uncertainties in predicting future results and conditions. All statements, other than statements of historical fact, are forward-looking statements. Certain factors that could cause the actual results to differ materially from those projected in these forward-looking statements include, but are not limited to the following: variations in weather; changes in the regulatory environment; customers' preferences on energy sources; general economic conditions; increased competition; fluctuations in supply, demand, transmission capacity and prices for energy commodities; and other uncertainties, all of which are difficult to predict, and many of which are beyond the control of Unitil Corporation.

For more information please contact:

Christopher Goulding – Investor Relations
Phone: 603-773-6466
Email: gouldingc@unitil.com

Amanda Vicinanzo – External Affairs
Phone: 603-691-7784
Email: vicinanzoa@unitil.com


Risks

  • Variations in weather impacting energy demand and supply reliability.
  • Changes in regulatory environment affecting operations and profitability.
  • Uncertainties in energy commodity prices and supply-demand dynamics influencing financial performance.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026